Purchase this article with an account.
Sandrine A. Zweifel, Magdalena Toenz, Lukas Pfenninger, Matthias D. Becker, Stephan Michels; Intravitreal Anti-VEGF Therapy For Retinal Macroaneurysm. Invest. Ophthalmol. Vis. Sci. 2012;53(14):966.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of intravitreal anti-vascular endothelial growth factor (VEGF) therapy using bevacizumab or ranibizumab for retinal macroaneurysms with macular exudation.
In a retrospective interventional case series patients with macroaneurysms were treated with either 1.25mg intravitreal bevacizumab or 0.5mg ranibizumab as first line therapy. Patients were imaged by fluorescein angiography and optical coherence tomography (OCT). Retreatment was performed in case of persistent intraretinal or subretinal fluid in OCT.
Ten patients (10 eyes) with macroaneurysm involving the macula were treated with an average of 3.0 intravitreal anti-VEGF injections. Mean best corrected visual acuity (BCVA) of all patients improved by 17 letters from baseline to last follow-up visit. In 7 out of 10 patients, the fovea was affected by the secondary edema. In cases with foveal involvement, central retinal thickness decreased from 366µm at baseline to 266µm at last follow-up visit. In the course of treatment 8 out of 10 patients showed evidence of closure of the macroaneurysm.
Intravitreal anti-VEGF therapy appears to be a promising treatment alternative to laser treatment in cases of retinal macroaneurysms with macular exudation.
This PDF is available to Subscribers Only